Two decades of cancer genetics: From specificity to pleiotropic networks

Cold Spring Harbor Symposia on Quantitative Biology

Volumn 70, Issue , 2005, Pages 83-91

  Grisendi, S ^a   Pandolfi, P P ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NUCLEOPHOSMIN; CELL MARKER; CYCLIN DEPENDENT KINASE 2; IMMUNOGLOBULIN; MOLECULAR MARKER; ONCOPROTEIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN P53; PROTEIN TYROSINE KINASE; RETINOBLASTOMA PROTEIN; RETINOIC ACID RECEPTOR;

CANCER GENETICS; CANCER SUSCEPTIBILITY; CARCINOGENESIS; CELL CYCLE; CELL TYPE; CENTROSOME; CHROMOSOME TRANSLOCATION; CONFERENCE PAPER; DNA DAMAGE; GENE; HEMATOLOGIC DISEASE; HEMATOPOIESIS; LEUKEMIA; LYMPHOMA; MOLECULAR GENETICS; ONCOGENE C MYC; PATHOGENESIS; PLEIOTROPY; PRIORITY JOURNAL; PROMOTER REGION; PROMYELOCYTIC LEUKEMIA; PROTO ONCOGENE; SOLID TUMOR; TUMOR SUPPRESSOR GENE; APOPTOSIS; ARTICLE; BURKITT LYMPHOMA; CELL PROLIFERATION; FLUORESCENCE IN SITU HYBRIDIZATION; GENE REARRANGEMENT; HEMATOLOGIC MALIGNANCY; HUMAN; NONHUMAN; PHOSPHORYLATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION;

ANIMALS; CENTROSOME; GENE DOSAGE; GENES, MYC; GENES, TUMOR SUPPRESSOR; HUMANS; LEUKEMIA; LYMPHOMA; MICE; MODELS, GENETIC; MUTATION; NEOPLASMS; NUCLEAR PROTEINS; TRANSLOCATION, GENETIC;

EID: 33746446718     PISSN: 00917451     EISSN: None     Source Type: Book Series    
DOI: 10.1101/sqb.2005.70.023     Document Type: Conference Paper

References (53)

1. Adams J.M., Harris A.W., Pinkert C.A., Corcoran L.M., Alexander W.S., Cory S., Palmiter R.D., and Brinster R.L. 1985. The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice. Nature 318: 533.
2. Ahn J.Y., Liu X., Cheng D., Peng J., Chan P.K., Wade P.A., and Ye K. 2005. Nucleophosmin/B23, a nuclear PI(3,4,5)P(3) receptor, mediates the anti-apoptotic actions of NGF by inhibiting CAD. Mol. Cell 18: 435.
3. Arvanitis C. and Felsher D.W. 2005. Conditionally MYC: Insights from novel transgenic models. Cancer Lett. 226: 95.
4. Bernassola F., Oberst A., Melino G., and Pandolfi P.P. 2005. The promyelocytic leukaemia protein tumour suppressor functions as a transcriptional regulator of p63. Oncogene 24: 6982.
5. Bernassola F., Salomoni P., Oberst A., Di Como C.J., Pagano M., Melino G., and Pandolfi P.P. 2004. Ubiquitin-dependent degradation of p73 is inhibited by PML. J. Exp. Med. 199: 1545.
6. Bertwistle D., Sugimoto M., and Sherr C.J. 2004. Physical and functional interactions of the Arf tumor suppressor protein with nucleophosmin/B23. Mol. Cell. Biol. 24: 985.
7. Brady S.N., Yu Y., Maggi L.B., Jr., and Weber J.D. 2004. ARF impedes NPM/B23 shuttling in an Mdm2-sensitive tumor suppressor pathway. Mol. Cell. Biol. 24: 9327.
8. Colombo E., Marine J.C., Danovi D., Falini B., and Pelicci P.G. 2002. Nucleophosmin regulates the stability and transcriptional activity of p53. Nat. Cell Biol. 4: 529.
9. Dalla-Favera R., Bregni M., Erikson J., Patterson D., Gallo R.C., and Croce C.M. 1982. Human c-myc oncogene is located on the region of chromosome 8 that is translocated in Burkitt lymphoma cells. Proc. Natl. Acad. Sci. 79: 7824.
10. Falini B., Mecucci C., Tiacci E., Alcalay M., Rosati R., Pasqualucci L., La Starza R., Diverio D., Colombo E., Santucci A., Bigerna B., Pacini R., Pucciarini A., Liso A., Vignetti M., Fazi P., Meani N., Pettirossi V., Saglio G., Mandelli F., Lo-Coco F., Pelicci P.G., and Martelli M.F. 2005. Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N. Engl. J. Med. 352: 254.
11. Grisendi S. and Pandolfi P.P. 2005. NPM mutations in acute myelogenous leukemia. N. Engl. J. Med. 352: 291.
12. Grisendi S., Bernardi R., Rossi M., Cheng K., Khandker L., Manova K., and Pandolfi P.P. 2005. Role of nucleophosmin in embryonic development and tumorigenesis. Nature 437: 147.
13. Guo A., Salomoni P., Luo J., Shih A., Zhong S., Gu W., and Pandolfi P.P. 2000. The function of PML in p53-dependent apoptosis. Nat. Cell Biol. 2: 730.
14. Gurrieri C., Capodieci P., Bernardi R., Scaglioni P.P., Nafa K., Rush L.J., Verbel D.A., Cordon-Cardo C., and Pandolfi P.P. 2004. Loss of the tumor suppressor PML in human cancers of multiple histologic origins. J. Natl. Cancer Inst. 96: 269.
15. Halmos B., Huettner C.S., Kocher O., Ferenczi K., Karp D.D., and Tenen D.G. 2002. Down-regulation and antiproliferative role of C/EBPalpha in lung cancer. Cancer Res. 62: 528.
16. Hingorani K., Szebeni A., and Olson M.O. 2000. Mapping the functional domains of nucleolar protein B23. J. Biol. Chem. 275: 24451.
17. Itahana K., Bhat K.P., Jin A., Itahana Y., Hawke D., Kobayashi R., and Zhang Y. 2003. Tumor suppressor ARF degrades B23, a nucleolar protein involved in ribosome biogenesis and cell proliferation. Mol. Cell 12: 1151.
18. Jensen K., Shiels C., and Freemont P.S. 2001. PML protein isoforms and the RBCC/TRIM motif. Oncogene 20: 7223.
19. Korgaonkar C., Hagen J., Tompkins V., Frazier A.A., Allamargot C., Quelle F.W., and Quelle D.E. 2005. Nucleophosmin (B23) targets ARF to nucleoli and inhibits its function. Mol. Cell. Biol. 25: 1258.
20. Kurki S., Peltonen K., Latonen L., Kiviharju T.M., Ojala P.M., Meek D., and Laiho M. 2004. Nucleolar protein NPM interacts with HDM2 and protects tumor suppressor protein p53 from HDM2-mediated degradation. Cancer Cell 5: 465.
21. Lanni J.S. and Jacks T. 1998. Characterization of the p53-dependent postmitotic checkpoint following spindle disruption. Mol. Cell. Biol. 18: 1055.
22. Levine A.J. 1997. p53, the cellular gatekeeper for growth and division. Cell 88: 323.
23. Li J., Zhang X., Sejas D.P., and Pang Q. 2005. Negative regulation of p53 by nucleophosmin antagonizes stress-induced apoptosis in human normal and malignant hematopoietic cells. Leuk. Res. 29: 1415.
24. Li J., Zhang X., Sejas D.P., Bagby G.C., and Pang Q. 2004. Hypoxia-induced nucleophosmin protects cell death through inhibition of p53. J. Biol. Chem. 279: 41275.
25. Li Q.L., Ito K., Sakakura C., Fukamachi H., Inoue K., Chi X.Z., Lee K.Y., Nomura S., Lee C.W., Han S.B., Kim H.M., Kim W.J., Yamamoto H., Yamashita N., Yano T., Ikeda T., Itohara S., Inazawa J., Abe T., Hagiwara A., Yamagishi H., Ooe A., Kaneda A., Sugimura T., Ushijima T., Bae S.C., and Ito Y. 2002. Causal relationship between the loss of RUNX3 expression and gastric cancer. Cell 5: 113.
26. Lin H.K., Bergmann S., and Pandolfi P.P. 2004. Cytoplasmic PML function in TGF-beta signalling. Nature 431: 205.
27. Melnick A. and Licht J.D. 1999. Deconstructing a disease: RARα, its fusion partners, and their roles in the pathogenesis of acute promyelocytic leukemia. Blood 93: 3167.
28. Mendes-da-Silva P., Moreira A., Duro-da-Costa J., Matias D., and Monteiro C. 2000. Frequent loss of heterozygosity on chromosome 5 in non-small cell lung carcinoma. Mol. Pathol. 53: 184.
29. Morgenbesser S.D. and DePinho R.A. 1994. Use of transgenic mice to study myc family gene function in normal mammalian development and in cancer. Semin. Cancer Biol. 5: 21.
30. Morris S.W., Kirstein M.N., Valentine M.B., Dittmer K.G., Shapiro D.N., Saltman D.L., and Look A.T. 1994. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. Science 263: 1281.
31. Nesbit C.E., Tersak J.M., and Prochownik E.V. 1999. MYC oncogenes and human neoplastic disease. Oncogene 18: 3004.
32. Okuda M., Horn H.F., Tarapore P., Tokuyama Y., Smulian A.G., Chan P.K., Knudsen E.S., Hofmann I.A., Snyder J.D., Bove K.E., and Fukasawa K. 2000. Nucleophosmin/B23 is a target of CDK2/cyclin E in centrosome duplication. Cell 103: 127.
33. Olney H.J. and Le Beau M.M. 2002. The cytogenetics and molecular biology of the myelodysplastic syndromes. In The myelodysplastic syndromes, pathobiology and clinical management (ed. J.M. Bennet), p. 89. Marcel Dekker, New York.
34. Oster S.K., Ho C.S.W., Soucie E.L., and Penn L.Z. 2002. The myc oncogene: Marvelously complex. Adv. Cancer Res. 84: 81.
35. Pang Q., Christianson T.A., Koretsky T., Carlson H., David L., Keeble W., Faulkner G.R., Speckhart A., and Bagby G.C. 2003. Nucleophosmin interacts with and inhibits the catalytic function of eukaryotic initiation factor 2 kinase PKR. J. Biol. Chem. 278: 417091.
36. Pearson M., Carbone R., Sebastiani C., Cioce M., Fagioli M, Saito S., Higashimoto Y., Appella E., Minucci S., Pandolfi P.P., and Pelicci P.G. 2000. PML regulates p53 acetylation and premature senescence induced by oncogenic Ras. Nature 406: 207.
37. Piazza F., Gurrieri C., and Pandolfi P.P. 2001. The theory of APL. Oncogene 20: 7216.
38. Redner R.L., Rush E.A., Faas S., Rudert W.A., and Corey S. J. 1996. The t(5;17) variant of acute promyelocytic leukemia expresses a nucleophosmin- retinoic acid receptor fusion. Blood 87: 882.
39. Rego E.M., Wang Z.G., Peruzzi D., He L.Z., Cordon-Cardo C., and Pandolfi P.P. 2001. Role of promyelocytic leukemia (PML) protein in tumor suppression. J. Exp. Med. 193: 521.
40. Salomoni P. and Pandolfi P.P. 2002. The role of PML in tumor suppression. Cell 108: 165.
41. Savkur R.S. and Olson M.O. 1998. Preferential cleavage in pre-ribosomal RNA by protein B23 endoribonuclease. Nucleic Acids Res. 26: 4508.
42. Spencer C.A. and Groudine M. 1991. Control of c-myc regulation in normal and neoplastic cells. Adv. Cancer Res. 56: 1.
43. Tomlins S.A., Rhodes D.R., Perner S., Dhanasekaran S.M., Mehra R., Sun X., Varambally S., Cao X., Tchinda J., Kuefer R., Lee C., Montie J.E., Shah R.B., Pienta K.J., Rubin M.A., and Chinnaiyan A.M. 2005. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 310: 644.
44. Vennstrom B., Sheiness D., Zabielski J., and Bishop J.M. 1982. Isolation and characterization of c-myc, a cellular homolog of the oncogene (v-myc) of avian myelocytomatosis virus strain 29. J. Virol. 42: 773.
45. Wang Z.G., Ruggero D., Ronchetti S., Zhong S., Gaboli M., Rivi R., and Pandolfi P.P. 1998. PML is essential for multiple apoptotic pathways. Nat. Genet. 20: 266.
46. Wu M.H., Chang J.H., and Yung B.Y.M. 2002. Resistance to UV-induced cell-killing in nucleophosmin/B23 over-expressed NIH3T3 fibroblasts: Enhancement of DNA repair and up-regulation of PCNA in association with nucleophosmin/ B23 over-expression. Carcinogenesis 23: 93.
47. Xu X., Qiao W., Linke S.P., Cao L., Li W.M., Furth P.A., Harris C.C., and Deng C.X. 2001. Genetic interactions between tumor suppressor Brca1 and p53 in apoptosis, cell cycle and tumorigenesis. Nat. Genet. 28: 266.
48. Xu X., Weaver Z., Linke S.P., Li C., Gotay J., Wang X.W., Harris C.C., Ried T., and Deng C.X. 1999. Centrosome amplification and defective G2-M cell cycle check-point induce genetic instability in BRCA1 exon 11 isoform-deficient cells. Mol. Cell 3: 389.
49. Yao J., Fu C., Ding X., Guo Z., Zenreski A., Chen Y., Ahmed K., Liao J., Dou Z., and Yao X. 2004. Nek2A kinase regulates the localization of numatrin to centrosome in mitosis. FEBS Lett. 575: 112.
50. Yoneda-Kato N., Look A.T., Kirstein M.N., Valentine M.B., Raimondi S.C., Cohen K.J., Carroll A.J., and Morris S.W. 1996. The t(3;5)(q25.1;q34) of myelodysplastic syndrome and acute myeloid leukemia produces a novel fusion gene, NPM-MLF1. Oncogene 12: 265.
51. Zhang H., Shi X., Paddon H., Hampong M., Dai W., and Pelech S. 2004. B23/nucleophosmin serine 4 phosphorylation mediates mitotic functions of polo-like kinase 1. J. Biol. Chem. 279: 35726.
52. Zhong S., Salomoni P. ,and Pandolfi P.P. 2000a. The transcriptional role of PML and the nuclear body. Nat. Cell Biol. 2: E85.
53. Zhong S., Muller S., Ronchetti S., Freemont P.S., Dejean A., and Pandolfi P.P. 2000b. Role of SUMO-1 modified PML in nuclear body formation. Blood 95: 2748.